A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Inclusion Criteria: * Histologically confirmed cancer patients without standard of care * ECOG performance status 0, 1, or 2 * Adequate organ and bone marrow function Exclusion Criteria: * Need for a major surgery or radiation therapy during the study * History of hypersensitivity to S-1 * Known dihydropyrimidine dehydrogenase deficiency * Uncontrolled hypertension * History of brain metastases * Ascites requiring drainage * Pregnancy or breastfeeding * Patients who have previously been treated with AVE0005 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.